» Articles » PMID: 34768690

Hunger and Satiety Peptides: Is There a Pattern to Classify Patients with Prader-Willi Syndrome?

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Nov 13
PMID 34768690
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperphagia is one of the main problems of patients with Prader-Willi syndrome (PWS) to cope with everyday life. The underlying mechanisms are not yet well understood. Gut-brain hormones are an interrelated network that may be at least partially involved. We aimed to study the hormonal profile of PWS patients in comparison with obese and healthy controls. Thirty adult PWS patients (15 men; age 27.5 ± 8.02 years; BMI 32.4 ± 8.14 kg/m), 30 obese and 30 healthy controls were studied before and after eating a hypercaloric liquid diet. Plasma brain-derived neurotrophic factor (BDNF), leptin, total and active ghrelin, peptide YY (PYY), pancreatic polypeptide (PP), Glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and amylin were determined at times 0', 30', 60' and 120'. Cluster analysis was used. When considering all peptides together, two clusters were established according to fasting hormonal standardized concentrations. Cluster 1 encompassed most of obese (25/30) and healthy controls (28/30). By contrast, the majority of patients with PWS were located in Cluster 2 (23/27) and presented a similar fasting profile with hyperghrelinemia, high levels of leptin, PYY, GIP and GLP-1, compared to Cluster 1; that may reflect a dysfunction of these hunger/satiety hormones. When peptide behavior over the time was considered, PP concentrations were not sustained postprandially from 60 min onwards in Cluster 2. BDNF and amylin did not help to differentiate the two clusters. Thus, cluster analysis could be a good tool to distinguish and characterize the differences in hormone responses between PWS and obese or healthy controls.

Citing Articles

Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.

Miller J, Berry S, Ismail E Paediatr Drugs. 2025; .

PMID: 39873961 DOI: 10.1007/s40272-025-00681-x.


Serum Ghrelin and Glucagon-like Peptide 1 Levels in Children with Prader-Willi and Bardet-Biedl Syndromes.

Turkkahraman D, Tekin S, Gullu M, Aykal G J Clin Res Pediatr Endocrinol. 2023; 16(2):146-150.

PMID: 38099591 PMC: 11590730. DOI: 10.4274/jcrpe.galenos.2023.2023-7-7.


Prader-Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach.

Barrea L, Vetrani C, Fintini D, de Alteriis G, Panfili F, Bocchini S Curr Obes Rep. 2022; 11(4):263-276.

PMID: 36063285 PMC: 9729321. DOI: 10.1007/s13679-022-00478-w.

References
1.
Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H . Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011; 96(8):E1314-9. DOI: 10.1210/jc.2011-0038. View

2.
Delparigi A, Tschop M, Heiman M, Salbe A, Vozarova B, Sell S . High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab. 2002; 87(12):5461-4. DOI: 10.1210/jc.2002-020871. View

3.
Gimenez-Palop O, Gimenez-Perez G, Mauricio D, Gonzalez-Clemente J, Potau N, Berlanga E . A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin Endocrinol (Oxf). 2007; 66(2):198-204. DOI: 10.1111/j.1365-2265.2006.02707.x. View

4.
Tomita T, Greeley Jr G, Watt L, Doull V, Chance R . Protein meal-stimulated pancreatic polypeptide secretion in Prader-Willi syndrome of adults. Pancreas. 1989; 4(4):395-400. DOI: 10.1097/00006676-198908000-00001. View

5.
Berntson G, Zipf W, ODorisio T, Hoffman J, CHANCE R . Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides. 1993; 14(3):497-503. DOI: 10.1016/0196-9781(93)90138-7. View